Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Future Medical Device Companies -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (36)	11/3/2006 9:24:51 PM
From: dr.praveen	Respond to of 136

Reducing Lead Apron Wear Time and Radiation Exposure with Remote-Controlled PCI: The Corindus CorPath™ - Mark Paquin, Tampa, Florida; Reviewed by Reviewed by David F. Kong, MD, AM at Duke Clinical Research Institute, Durham, North Carolina, and a member of the Cath Lab Digest editorial board ----------------------------------------------------- Co's website:http://www.corindus.com/index.asp Recent presentation:http://www.corindus.com/news%5C35.pdf ----------------------------------------------------- Advances in interventional cardiology have enabled operators to increase proficiency, while minimizing patient injury and risk. Other technological advancements, seen in areas of minimally invasive medicine, such as robotic-assisted surgery, have inspired engineers to explore approaches for improving outcomes and decreasing technical failure rates for percutaneous coronary interventions (PCI). Furthermore, the volume of patients that are now being referred to PCI and the time demands placed on interventional cardiologists, put operators at increased risk of occupational hazards. The ability to improve safety and the personal health of operators while maintaining the outcome of these procedures has lead to the development of beneficial technologies, such as Corindus’ CorPath™ (Auburndale, MA), a remote control catheterization system that allows operators to mechanically maneuver devices as specified by the physician using a remote workstation. CorPath is designed to use conventional guide wires, balloon catheters, and stents through coronary arteries via a computerized system. >>>

To: dr.praveen who wrote (36)	11/4/2006 10:43:49 AM
From: semi_infinite	Read Replies (3) \| Respond to of 136

Hansen Medical -- really stupid IPO when FDA issues under the cover have to be exposed for everyone to see. If the FDA rejects the 510K attempt and make them go the PMA route (and that looks increasingly probable), the stock will be cut in half if not more. So, take the IPO price, cut it in half and I may be interested in kicking the tires. I don't understand the VC's pushing them into combat when basic training is not complete.